C12N 2840/80
From vertebrates
Official title: from vertebrates
C12N2840/80 (From vertebrates) appears on 50 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 50
- Published applications
- 47
- Assignees
- 42
- Inventors
- 105
- Latest grant
- 25 Jun 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 3 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 2 |
| 2005 | 3 | 4 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 2 | 1 |
| 2010 | 0 | 3 |
| 2011 | 1 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 3 |
| 2014 | 3 | 7 |
| 2015 | 7 | 9 |
| 2016 | 7 | 1 |
| 2017 | 3 | 3 |
| 2018 | 2 | 0 |
| 2019 | 1 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 1 | 2 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Method of detecting Polycomb Repressive Complex activity25 Jun 2024US 12,018,253 B2Imba—Institut FüR Molekulare Biotechnologie GmbH
- Tri-segmented arenaviruses as vaccine vectors28 Jul 2020US 10,722,564 B2Universite De Geneve
- Modified polynucleotides10 Dec 2019US 10,501,512 B2ModernaTX, Inc.
- Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof27 Feb 2018US 9,902,969 B2Korea Research Institute of Bioscience and Biotechnology
- Modified polynucleotides for the production of cosmetic proteins and peptides30 Jan 2018US 9,878,056 B2ModernaTX, Inc.
- Nucleic acid construct and use thereof18 Sep 2025US 2025/0288659 A1Shanghai Regenelead Therapies Co., Ltd.
- Modified polynucleotides for the production of proteins associated with human disease3 Oct 2024US 2024/0327476 A1ModernaTX, Inc.
- Tri-segmented arenaviruses as vaccine vectors14 Mar 2024US 2024/0082376 A1Universite De Geneve
- Tri-segmented arenaviruses as vaccine vectors20 May 2021US 2021/0145950 A1Universite De Geneve
- Modified polynucleotides for the production of proteins associated with human disease22 Apr 2021US 2021/0115101 A1ModernaTX, Inc.
Most cited
By later US patents
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins198US 9,303,079 B2Moderna Therapeutics, Inc. · 2016
- Recombinant negative strand RNA virus expression systems and vaccines171US 5,854,037 AMount Sinai School of Medicine of the City University of New York · 1998
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998